Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1
Telomir Pharmaceuticals (TELO), a biotech innovator focused on age-reversal science, announced a $3 million equity investment from its largest shareholder, The Bayshore Trust. The deal was structured as a straight equity sale—1 million restricted shares at $3.00 per share—representing an 18% premium to Telomir’s closing stock price of $2.54 at the time of execution.
Importantly, the financing includes no warrants, no discounts, and no convertible features, signaling strong insider conviction and a commitment to shareholder-friendly terms.
This follows a previous $1 million investment at $7.00 per share in December 2024 from The Starwood Trust, an entity affiliated with the same shareholder group. Telomir also maintains access to a $5 million undrawn, non-dilutive line of credit from the same affiliate, bringing its total insider-backed funding potential to $9 million.
“We’ve now raised $4 million in equity and secured an additional $5 million in non-dilutive capital—all without toxic structures,” said Erez Aminov, Chairman and CEO of Telomir. “This capital will directly support the IND submission for Telomir-1 and early clinical work in a rare disease setting.”
Telomir-1, the company’s lead candidate, is a first-in-class small molecule designed to reverse cellular aging by targeting five core biological processes, including mitochondrial dysfunction and telomere shortening.
In parallel, the company is developing Telomir-Ag2, a stabilized Silver(II) compound aimed at combating drug-resistant infections.
With a focus on long-term value creation and disciplined capital management, Telomir’s recent raise positions it well to pursue regulatory milestones and clinical progress in the months ahead.
You might like this article:Elon Musk Confirms Tesla and xAI to Continue Buying AI Chips from Nvidia and AMD
